Jiménez-Ubieto, Ana
Poza, María
Martin-Muñoz, Alejandro
Ruiz-Heredia, Yanira
Dorado, Sara http://orcid.org/0000-0002-4144-0315
Figaredo, Gloria
Rosa-Rosa, Juan Manuel
Rodriguez, Antonia
Barcena, Carmen
Navamuel, Laura Parrilla
Carrillo, Jaime
Sanchez, Ricardo http://orcid.org/0000-0002-6383-0381
Rufian, Laura
Juárez, Alexandra
Rodriguez, Margarita
Wang, Chongwu
de Toledo, Paula
Grande, Carlos
Mollejo, Manuela
Casado, Luis-Felipe
Calbacho, María http://orcid.org/0000-0001-8106-4863
Baumann, Tycho
Rapado, Inmaculada
Gallardo, Miguel http://orcid.org/0000-0002-3699-9130
Sarandeses, Pilar
Ayala, Rosa
Martínez-López, Joaquín
Barrio, Santiago http://orcid.org/0000-0003-0793-3535
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI21/00314, PI 19/01430, PI21/00314)
CRIS cancer foundation
Article History
Received: 31 July 2022
Revised: 9 December 2022
Accepted: 19 December 2022
First Online: 3 January 2023
Competing interests
: RA, JML, and SB are equity shareholders of Altum Sequencing Co. LLFC received honoraria and received research funding from Roche, Novartis, Astra Zeneca, Janssen, B.M.S., Pfizer and Incyte. The remaining authors declare no competing financial interests.